HCW Biologics Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 2929 N COMMERCE PKWY, MIRAMAR, FL, 33025
Mailing Address 2929 N COMMERCE PKWY, MIRAMAR, FL, 33025
Phone 954-842-2024
Fiscal Year End 1231
EIN 825024477
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 13, 2026 | View on SEC |
| S-1/A IPO registration amendment | February 13, 2026 | View on SEC |
| S-1 IPO registration statement | February 11, 2026 | View on SEC |
| S-1 IPO registration statement | January 9, 2026 | View on SEC |
| 8-K Current report of material events | December 31, 2025 | View on SEC |
| 8-K Current report of material events | November 20, 2025 | View on SEC |
| 8-K Current report of material events | November 19, 2025 | View on SEC |
| 8-K Current report of material events | November 18, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 14, 2025 | View on SEC |
| 8-K Current report of material events | November 14, 2025 | View on SEC |
Material Events
8-K Financial Distress December 31, 2025
High Impact
- HCW Biologics Inc. believes it has successfully resolved a major financial issue that could have led to Nasdaq delisting.
- The company has increased its stockholders' equity to meet Nasdaq's minimum $2.5 million requirement.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.